Characterization of lipid profile in primary health care users in Portugal;Caracterização do perfil lipídico nos utentes dos cuidados de saúde primários em Portugal

Revista Portuguesa de Cardiologia

Volumn 32, Issue 12, 2013, Pages 987-996

  Cortez Dias, Nuno ^a,b,c   Martins, Susana Robalo ^a,c   Belo, Adriana ^d   Fiúza, Manuela ^a,c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Ministerio da Saude Portuguese   (Portugal)

^c UNIVERSITY OF LISBON   (Portugal)

^d Centro Nacional de Colecção de Dados em Cardiologia   (Portugal)

Author keywords

Dyslipidemia; Hypercholesterole mia; Hypertrigly ceridemia; Prevalence

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION DENSITY; PORTUGAL; POSTMENOPAUSE; PRIMARY HEALTH CARE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; DYSLIPIDEMIAS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; PORTUGAL; PRIMARY HEALTH CARE; TRIGLYCERIDES; YOUNG ADULT;

EID: 84893673425     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2013.06.008     Document Type: Article

References (36)

1. Correia M, Silva MR, Matos I, et al. Prospective community-based study of stroke in Northern Portugal: Incidenceand case fatality in rural and urban populations. Stroke. 2004;35:2048-53.
2. Goncalves AF, Cardoso SM. The prevalence of cerebrovascularstroke in Coimbra. Acta Med Port. 1997;10:543-50.
3. de Sá P, Dias JA, Miguel JM. The evolution of mortality fromischemic heart disease and cerebrovascular diseases in Portugalin the decade of the 80s. Acta Med Port. 1994;7:71-81.
4. Mirzaei M, Truswell AS, Arnett K, et al. Cerebrovascular diseasein 48 countries: Secular trends in mortality. J Neurol NeurosurgPsychiatry. 2012;83:138-45.
5. Stamler J, Daviglus ML, Garside DB, et al. Relationship of base-line serum cholesterol levels in 3 large cohorts of younger mento long-term coronary, cardiovascular, and all-cause mortalityand to longevity. JAMA. 2000;284:311-8.
6. Pencina MJ, d'Agostino Sr RB, Larson MG, et al. Predicting the30-year risk of cardiovascular disease: The Framingham heartstudy. Circulation. 2009;119:3078-84.
7. Gouveia M, Borges M, Costa J, et al. Burden of diseasefrom hypercholesterolemia in Portugal. Rev Port Cardiol. 2004;23:255-70.
8. Gouveia M, Borges M, Costa J, et al. Costs of illnessdue to hypeercholesterolemia in Portugal. Rev Port Cardiol. 2004;23:1037-54.
9. Gotto Jr AM, Whitney E, Stein EA, et al. Relation betweenbaseline and on-treatment lipid parameters and first acutemajor coronary events in the Air Force/Texas Coronary Athe-rosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477-84.
10. Shepherd J, Cobbe SM, Ford I, et al. , West of Scotland Coronary Prevention Study Group. Prevention of coronary heart diseasewith pravastatin in men with hypercholesterolemia. N Engl JMed. 1995;333:1301-7.
11. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovas-cular events with an antihypertensive regimen of amlodipineadding perindopril as required versus atenolol adding ben-droflumethiazide as required, in the Anglo-ScandinavianCardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906.
12. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety ofcholesterol-lowering treatment: prospective meta-analysisof data from 90,056 participants in 14 randomised trials ofstatins. Lancet. 2005;366:1267-78.
13. de Caterina R, Scarano M, Marfisi R, et al. Cholesterol- loweringinterventions and stroke: Insights from a meta-analysis of ran-domized controlled trials. J Am Coll Cardiol. 2010;55:198-211.
14. Catapano AL, Reiner Z, de Backer BG, et al.
15. Atherosclerosis. 2011;217:3-46.
16. National Cholesterol Education Program (NCEP) Expert Panelon Detection, Evaluation, Treatment of High Blood Choleste-rol in Adults (Adult Treatment Panel III), Third Report of theNational Cholesterol Education Program (NCEP) Expert Panel onDetection. Evaluation, and Treatment of High Blood Choleste-rol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
17. Genest J, Frohlich J, Fodor G, et al. Recommendations forthe management of dyslipidemia and the prevention of car-diovascular disease: Summary of the 2003 update. CMAJ. 2003;169:921-4.
18. Nunes L, Pipa J, Nascimento C, et al. Prevalence of several car-diovascular risk factors in a population in the municipality ofViseu. Rev Port Cardiol. 1997;16:703-7.
19. Schneider V, Cruz J, Lopes D, et al. The prevalence of the prin-cipal cardiovascular risk factors in the population of the Azores. Rev Port Cardiol. 1995;14:1019-27.
20. von Hafe P, Lopes C, Maciel MJ, et al. The clustering of cardio-vascular risk factors in the urban population of Porto. Acta MedPort. 1998;11:1059-64.
21. Santiago LM. Incidence and prevalence of hypercholesterolemiain Portugal. Rev Port Cardiol. 2003;22:1283-4.
22. dos Reis RP, dos Reis HP. Cardiovascular risk factors in thelist of patients of a general practitioner. Rev Port Cardiol. 1990;9:607-12.
23. Costa J, Borges M, Oliveira E, et al. Incidence and prevalenceof hypercholesterolemia in Portugal: A systematic review. PartI. Rev Port Cardiol. 2003;22:569-77.
24. Costa J, Borges M, Oliveira E. Incidence and prevalence ofhypercholesterolemia in Portugal: A systemic review. Part II. Rev Port Cardiol. 2003;22:683-702.
25. Costa J, Borges M, Oliveira E, et al. Incidence and prevalenceof hypercholesterolemia in Portugal: A systematic review. PartIII. Rev Port Cardiol. 2003;22:829-36.
26. Fiuza M, Cortez-Dias N, Martins S, et al. Metabolic syndromein Portugal: Prevalence and implications for cardiovascularrisk-results from the VALSIM Study. Rev Port Cardiol. 2008;27:1495-529.
27. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCOREproject. Eur Heart J. 2003;24:987-1003.
28. do Carmo I, dos Santos O, Camolas J, et al. Overweight andobesity in Portugal: National prevalence in 2003-2005. Obes Rev. 2008;9:11-9.
29. Carreira HF, Pereira MF, Azevedo AF, et al. Trends of BMIand prevalence of overweight and obesity in Portugal (1995-2005): A systematic review. Public Health Nutr. 2012;15:972-81.
30. Sardinha LB, Santos DA, Silva AM, et al. Prevalence ofoverweight, obesity, and abdominal obesity in a representativesample of Portuguese adults. PLoS One. 2012;7:e47883.
31. Danaei GF, Finucane MM, Lin J, et al. National, regional, andglobal trends in systolic blood pressure since 1980: Systema-tic analysis of health examination surveys and epidemiologicalstudies with 786 country-years and 5. 4 million participants. Lan-cet. 2011;377:568-77.
32. Farzadfar FF, Finucane MM, Danaei G, et al. National, regio-nal, and global trends in serum total cholesterol since 1980:Systematic analysis of health examination surveys and epi-demiological studies with 321 country-years and 3. 0 millionparticipants. Lancet. 2011;377:578-86.
33. Gardner CD, Winkleby MA, Fortmann SP. Population frequencydistribution of non-high-density lipoprotein cholesterol (ThirdNational Health and Nutrition Examination Survey [NHANES III],1988-1994). Am J Cardiol. 2000;86:299-304.
34. Medrano MJ, Cerrato E, Boix R, et al. Cardiovascular risk factorsin Spanish population: Metaanalysis of cross-sectional studies. Med Clin (Barc). 2005;124:606-12.
35. Vegazo OF, Banegas JR, Civeira F, et al. Prevalence of dyslipide-mia in outpatients of the Spanish health service: The HISPALIPIDStudy. Med Clin (Barc). 2006;127:331-4.
36. Teixeira IJ, Escoval A, Schiappa M. Lipid-lowering drugs: Useand expenditure in Portugal (1995-2004). Rev Port Cardiol. 2007;26:475-93.